News summary
[Shanghai Pharmaceutical: I040 Obtained Clinical Trial Approval Notice] Securities Times e Company Newscryptogamestoplay, Shanghai Pharmaceutical (601607) announced on the evening of May 24cryptogamestoplay, the "I040" clinical trial application developed by the company received the "Drug Clinical Trial Approval Notice" approved and issued by the State Food and Drug Administration. I040 is acryptogamestoplay.cryptogamestoplay..
Newsletter text
[Shanghai Pharmaceutical: I040 Obtained Clinical Trial Approval Notice] Securities Times e Company News, Shanghai Pharmaceutical (601607) announced on the evening of May 24 that the "I040" clinical trial application developed by the company received the approval and issuance of the "Drug Clinical Trial Approval Notice" by the State Food and Drug Administration. I040 is a small molecule compound. Preclinical studies have shown that I040 can improve core symptoms in multiple animal models of depression and has good safety.